Abstract
Autosomal recessive cutis laxa type 2 (ARCL2), a syndrome of growth and developmental delay and redundant, inelastic skin, is caused by mutations in the a2 subunit of the vesicular ATPase H+-pump (ATP6V0A2). The goal of this study was to define the disease mechanisms that lead to connective tissue lesions in ARCL2. In a new cohort of 17 patients, DNA sequencing of ATP6V0A2 detected either homozygous or compound heterozygous mutations. Considerable allelic and phenotypic heterogeneity was observed, with a missense mutation of a moderately conserved residue p.P87L leading to unusually mild disease. Abnormal N- and/or mucin type O-glycosylation was observed in all patients tested. Premature stop codon mutations led to decreased ATP6V0A2 mRNA levels by destabilizing the mutant mRNA via the nonsense-mediated decay pathway. Loss of ATP6V0A2 either by siRNA knockdown or in ARCL2 cells resulted in distended Golgi cisternae, accumulation of abnormal lysosomes and multivesicular bodies. Immunostaining of ARCL2 cells showed the accumulation of tropoelastin (TE) in the Golgi and in large, abnormal intracellular and extracellular aggregates. Pulse-chase studies confirmed impaired secretion and increased intracellular retention of TE, and insoluble elastin assays showed significantly reduced extracellular deposition of mature elastin. Fibrillin-1 microfibril assembly and secreted lysyl oxidase activity were normal in ARCL2 cells. TUNEL staining demonstrated increased rates of apoptosis in ARCL2 cell cultures. We conclude that loss-of-function mutations in ATP6V0A2 lead to TE aggregation in the Golgi, impaired clearance of TE aggregates and increased apoptosis of elastogenic cells.
| Original language | English |
|---|---|
| Journal | Human Molecular Genetics |
| Volume | 18 |
| Issue number | 12 |
| Pages (from-to) | 2149-2165 |
| Number of pages | 17 |
| ISSN | 0964-6906 |
| DOIs | |
| Publication status | Published - 04.06.2009 |
Funding
We thank the patients and family members whose cooperation made this work possible, Prof. Han G. Brunner for referring patients to this study; Sara McKay, Prof. R. Santer and Dr Tsiakas for clinical data; Dr Katalin Csiszar for a fibroblast cell line; Dr Robert P. Mecham and Dr Guojun Bu for antibodies; Dr Takahisa Kanekiyo for advice on immunostaining; the Facility for Electron Microscopy Research (FEMR) at McGill University and the EM facility of the Anatomy Department of the Charité for ultrastructural analysis. This study was supported by the National Institutes of Health (HL084922 to Z.U.), by the Washington University Friedman Center for Aging (to Z.U.), the European Commission (LSHM-CT2005-512131, Euroglycanet to R.A.W.) and the Canadian Institutes of Health Research (MOP-86713 to E.C.D.). E.C.D is a Canada Research Chair.
Research Areas and Centers
- Research Area: Medical Genetics